Geographic Atrophy

According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

Catch up on a few of our top stories and ones you may have missed in 2023

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.

According to the study, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

They believe that these phenotypic differences in GA should be considered in different ethnicities because they may have implications in research and in interventions to slow progression of GA.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

The use of silicone-free syringes advised with these drops.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

"Modern Family" actor and his mother, Jamey, are sharing their family’s story of GA and AMD to raise awareness of the disease.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.